jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Advanced - Cardiac Profile

Heart

67 parameters

image

Report in 8Hrs

image

At Home

fastingrequire

Fasting Required

Details

Basic cardiac markers (e.g., cholesterol, triglycerides).

₹1,999₹3,245

38% OFF

Parameters

  • List of Tests
    • Calcium
    • Alkaline Phosphatase
    • hs-CRP
    • Lipoprotein (A)
    • SGOT
    • SGPT
    • Uric Acid
    • Homocysteine
    • Apoliprotein A1
    • Apoliprotein B
    • Apo B/A1
    • BUN
    • Creatinine
    • BUN/Creatinine
    • GGT
    • Iron
    • TIBC
    • Transferrin Saturation
    • Bilirubin Direct
    • Bilirubin Total
    • Bilirubin Indirect
    • Cholesterol/HDL
    • LDL/HDL
    • Non-HDL
    • VLDL
    • Total Cholesterol
    • Triglycerides
    • HDL
    • LDL
    • Albumin
    • Total Protein
    • A/G Ratio
    • Globulin
    • Free T3
    • Free T4
    • TSH
    • HbA1c
    • Estimated Average Glucose
    • CBC - Complete Hemogram

Advanced - Cardiac Profile

  • Why is it done?
    • Comprehensive assessment of cardiovascular risk factors and heart disease prevention through combined evaluation of lipid metabolism, inflammation markers, and cardiac biomarkers
    • Evaluation of lipid profile (Total Cholesterol, HDL, LDL, VLDL, Triglycerides) to assess atherosclerosis risk and dyslipidemia
    • Detection of advanced cardiac risk through lipoprotein(a), apolipoprotein ratios, and high-sensitivity C-reactive protein (hs-CRP)
    • Assessment of kidney function (BUN, Creatinine, BUN/Creatinine ratio) critical for determining cardiac risk and medication safety
    • Evaluation of liver function (SGOT, SGPT, Bilirubin, Albumin, GGT) to assess medication tolerance and overall metabolic health
    • Screening for metabolic disorders including diabetes (HbA1c, eAG), thyroid dysfunction (TSH, Free T3, Free T4), and gout (Uric Acid)
    • Evaluation of homocysteine, an independent cardiovascular risk factor, and iron metabolism indicators
    • Complete blood count assessment to detect anemia, infections, and hematologic disorders affecting cardiac function
    • Monitoring and screening for individuals with family history of heart disease, diabetes, hypertension, or metabolic syndrome
    • Pre-treatment baseline assessment before starting cardiovascular or metabolic medications
    • Periodic monitoring of patients with established coronary artery disease, heart failure, or other cardiac conditions
  • Normal Range
    • Calcium: 8.5-10.5 mg/dL (2.1-2.6 mmol/L) - Normal indicates appropriate mineral metabolism
    • Alkaline Phosphatase: 30-120 IU/L - Normal range suggests appropriate bone and liver function
    • hs-CRP: <1.0 mg/L (Low risk), 1.0-3.0 mg/L (Intermediate risk), >3.0 mg/L (High risk) - Lower levels indicate reduced inflammation and cardiovascular risk
    • Lipoprotein(a): <30 mg/dL - Values below 30 mg/dL are considered optimal; higher levels increase cardiovascular risk
    • SGOT (AST): 10-40 IU/L - Normal indicates appropriate liver function and minimal hepatic damage
    • SGPT (ALT): 7-56 IU/L - Normal range suggests healthy liver function and minimal cellular injury
    • Uric Acid: 3.5-7.2 mg/dL (men), 2.6-6.0 mg/dL (women) - Normal levels reduce gout and cardiovascular risk
    • Homocysteine: <11 μmol/L - Normal levels indicate low cardiovascular and thrombotic risk
    • Apolipoprotein A1: 120-240 mg/dL - Higher levels indicate protective effect against atherosclerosis
    • Apolipoprotein B: 50-130 mg/dL - Lower levels suggest reduced atherogenic particle burden
    • Apo B/A1 Ratio: <0.8 - Lower ratios indicate better cardiovascular protection
    • BUN: 7-20 mg/dL - Normal indicates appropriate kidney function and protein metabolism
    • Creatinine: 0.6-1.2 mg/dL (men), 0.5-1.1 mg/dL (women) - Normal range reflects adequate glomerular filtration rate
    • BUN/Creatinine Ratio: 10-20 - Normal ratio indicates balanced renal filtration and metabolism
    • GGT: 8-61 IU/L - Normal levels indicate appropriate liver and biliary function
    • Iron: 60-170 μg/dL (men), 50-150 μg/dL (women) - Normal levels support adequate oxygen transport and cardiac function
    • TIBC: 250-425 μg/dL - Normal iron binding capacity indicates proper iron transport mechanism
    • Transferrin Saturation: 20-50% - Normal saturation reflects appropriate iron metabolism and hemoglobin synthesis
    • Bilirubin Direct: 0.0-0.3 mg/dL - Normal indicates proper bile duct function
    • Bilirubin Total: 0.1-1.2 mg/dL - Normal range reflects appropriate liver and red blood cell metabolism
    • Bilirubin Indirect: 0.0-0.9 mg/dL - Normal indicates effective liver processing of bilirubin
    • Total Cholesterol: <200 mg/dL (Desirable), 200-239 mg/dL (Borderline high), ≥240 mg/dL (High) - Lower values reduce atherosclerotic disease risk
    • HDL Cholesterol: >40 mg/dL (men), >50 mg/dL (women) - Higher values provide cardiovascular protection
    • LDL Cholesterol: <100 mg/dL (Optimal), 100-129 mg/dL (Near optimal), 130-159 mg/dL (Borderline high), 160-189 mg/dL (High), ≥190 mg/dL (Very high) - Lower values reduce coronary artery disease risk
    • VLDL: <30 mg/dL - Normal range indicates appropriate triglyceride transport and reduced atherogenic risk
    • Triglycerides: <150 mg/dL (Normal), 150-199 mg/dL (Borderline high), 200-499 mg/dL (High), ≥500 mg/dL (Very high) - Normal levels reduce cardiovascular and pancreatitis risk
    • Total Cholesterol/HDL Ratio: <5.0 - Lower ratios indicate improved cardiovascular risk profile
    • LDL/HDL Ratio: <3.0 - Optimal ratio reflects favorable lipoprotein distribution
    • Non-HDL Cholesterol: <130 mg/dL - Normal indicates reduced atherogenic particle concentration
    • Albumin: 3.4-5.4 g/dL - Normal levels indicate appropriate nutritional status and liver synthesis
    • Total Protein: 6.0-8.3 g/dL - Normal range reflects balanced plasma protein composition
    • Albumin/Globulin Ratio: 1.0-2.5 - Normal ratio indicates balanced protein fractions
    • Globulin: 2.0-3.5 g/dL - Normal levels reflect appropriate immune function and protein synthesis
    • Free T3: 2.3-4.2 pg/mL - Normal range indicates appropriate thyroid hormone activity
    • Free T4: 0.7-1.9 ng/dL - Normal levels reflect appropriate thyroid function and metabolism
    • TSH: 0.4-4.0 mIU/L - Normal range indicates appropriate pituitary-thyroid axis function
    • HbA1c: <5.7% (Normal), 5.7-6.4% (Prediabetes), ≥6.5% (Diabetes) - Lower values indicate improved glucose control
    • Estimated Average Glucose (eAG): <100 mg/dL - Normal range reflects appropriate long-term glucose management
    • CBC - Complete Hemogram includes: Red Blood Cell Count (4.5-5.5 million/μL men, 4.1-5.1 million/μL women), Hemoglobin (13.5-17.5 g/dL men, 12.0-15.5 g/dL women), Hematocrit (38.8-50% men, 34.9-44.5% women), White Blood Cell Count (4.5-11.0 thousand/μL), Platelet Count (150-400 thousand/μL), and differential counts - all within normal ranges indicate appropriate hematologic function
  • Interpretation
    • Calcium - Elevated: Risk of hypercalcemia-related arrhythmias and hypertension; Decreased: Hypokalemia causing muscle weakness and cardiac conduction abnormalities; Factors: Vitamin D status, PTH levels, albumin concentration affect interpretation
    • Alkaline Phosphatase - Elevated: May indicate liver disease, bone disorders, or malignancy; Normal or low: Suggests preserved bone and liver health; Context: Age, pregnancy, and bone growth activity affect levels
    • hs-CRP - Elevated (>3.0 mg/L): Indicates significant inflammation and increased cardiac event risk; Intermediate (1.0-3.0): Suggests moderate inflammatory burden; Low (<1.0): Reduces cardiovascular risk estimate; Factors: Infection, smoking, obesity, stress elevate levels
    • Lipoprotein(a) - Elevated (>30 mg/dL): Increases thrombotic and atherosclerotic risk independent of other lipids; Genetic determination: Largely inherited, not significantly affected by lifestyle; High-risk individuals: Require aggressive management of other modifiable risk factors
    • SGOT (AST) - Elevated: May indicate hepatocellular injury, myocardial infarction, or muscle damage; Mild elevation: Often transient and benign; Significant elevation: Warrants further investigation; AST/ALT ratio: Ratio >1 suggests alcoholic liver disease
    • SGPT (ALT) - Elevated: More specific to liver injury than AST; Mild elevation: May result from statin use or viral hepatitis; Significant elevation: Indicates hepatic inflammation or necrosis; More sensitive: Reflects liver damage more specifically than AST
    • Uric Acid - Elevated: Increased gout risk, kidney stone formation, and cardiovascular disease; High levels: Correlate with hypertension and metabolic syndrome; Decreased: May indicate xanthine oxidase inhibitor use or genetic disorder; Dietary factors: Purines from red meat and seafood elevate levels
    • Homocysteine - Elevated (>11 μmol/L): Independent cardiovascular and thrombotic risk factor; Associations: Linked with stroke, MI, and atherosclerotic disease; Modifiable factors: B vitamins (B6, B12, folate) supplementation can reduce levels; Genetic factors: MTHFR mutations may impair metabolism
    • Apolipoprotein A1 - Elevated: Protective effect against atherosclerosis and cardiovascular disease; Lower levels: Associated with increased cardiovascular risk; Independent value: Provides additional risk stratification beyond traditional lipids
    • Apolipoprotein B - Elevated: Indicates increased atherogenic particle burden; Reflects total particle number: May be abnormal despite normal cholesterol; Better predictor: Superior to LDL cholesterol for cardiovascular risk in some patients
    • Apo B/A1 Ratio - Elevated (>0.8): Indicates higher cardiovascular risk from atherogenic particles predominance; Predictor: Superior to traditional lipid ratios for risk assessment; Lower ratios: Associated with improved cardiovascular outcomes
    • BUN - Elevated: May indicate dehydration, kidney disease, high protein diet, or muscle breakdown; Decreased: Suggests malnutrition, liver disease, or pregnancy; Must consider: Creatinine ratio for accurate interpretation
    • Creatinine - Elevated: Indicates reduced glomerular filtration rate and kidney disease; Requires assessment: GFR calculation for accurate kidney function evaluation; Factors: Muscle mass, age, gender affect baseline levels; Important for: Drug dosing and cardiovascular risk assessment
    • BUN/Creatinine Ratio - Elevated (>20): Suggests prerenal azotemia or dehydration; Normal ratio: Indicates intact renal function; Low ratio: May reflect liver disease or malnutrition
    • GGT - Elevated: Sensitive marker for liver disease, biliary obstruction, or alcohol use; More specific: For hepatobiliary disease than alkaline phosphatase; Factors: Enzyme-inducing medications increase levels; Interpretation: Must correlate with other liver enzymes
    • Iron - Elevated: Risk of hemochromatosis and iron-related organ damage; Decreased: May indicate anemia, blood loss, or nutritional deficiency; Context: Should be evaluated with TIBC and ferritin for complete assessment
    • TIBC - Elevated: Indicates iron deficiency or increased iron demand; Decreased: Suggests iron overload or liver disease; Interprets with: Iron level to determine iron status
    • Transferrin Saturation - Elevated (>50%): Raises hemochromatosis risk, requires genetic testing; Low (<20%): Suggests iron deficiency; 20-50%: Normal iron metabolism and appropriate utilization
    • Bilirubin Direct - Elevated: Indicates cholestasis or biliary obstruction; Normal: Suggests intact bile duct function; Must evaluate: With total bilirubin to determine cause
    • Bilirubin Total - Elevated: Indicates liver disease, hemolysis, or biliary obstruction; Mild elevation: <3 mg/dL may be benign; >3 mg/dL: Warrants investigation; Factors: Fasting, recent illness affect levels
    • Bilirubin Indirect - Elevated: Suggests hemolysis or impaired hepatic processing; Predominantly indirect: Indicates unconjugated hyperbilirubinemia; Must evaluate: With reticulocyte count to assess hemolysis
    • Total Cholesterol - Elevated (≥240): Significantly increases cardiovascular disease risk; 200-239: Borderline elevation requiring lifestyle modification; <200: Desirable but not guaranteeing low risk if other factors abnormal
    • HDL Cholesterol - Low levels: Strongest independent cardiovascular risk factor; Every 1 mg/dL decrease: Associated with 2-3% increased MI risk; Elevation: Protective through reverse cholesterol transport mechanism; Factors: Exercise, alcohol modestly, estrogen increase HDL
    • LDL Cholesterol - Elevated: Directly correlates with atherosclerotic plaque burden; Goal levels: Vary by cardiovascular risk category; <70 mg/dL: For very high-risk patients; Reduction benefit: Every 39 mg/dL reduction reduces MI risk by ~22%
    • VLDL - Elevated: Indicates increased triglyceride production and cardiovascular risk; Correlates with: Triglyceride levels as calculated from triglycerides/5; Metabolic syndrome: Often elevated with insulin resistance
    • Triglycerides - Elevated (≥200): Increases cardiovascular and pancreatitis risk; 150-199: Borderline elevation requiring dietary modification; Very high (≥500): Acute pancreatitis risk; Factors: Recent meals, alcohol, carbohydrates elevate levels significantly
    • Total Cholesterol/HDL Ratio - Elevated (>5.0): Indicates unfavorable lipid distribution; <5.0: Acceptable ratio; <3.5: Excellent lipid profile; Superior to: Single parameters for cardiovascular risk prediction
    • LDL/HDL Ratio - Elevated (>3.0): Associated with increased cardiovascular events; <2.0: Optimal protective ratio; Predictive: Stronger predictor than LDL alone in some populations
    • Non-HDL Cholesterol - Elevated (>130): Captures all atherogenic particles; May be abnormal: When triglycerides high despite normal LDL; Better predictor: Than LDL in hypertriglyceridemic patients; Goal: Same as LDL for each risk category
    • Albumin - Decreased: Indicates malnutrition, liver disease, or nephrotic syndrome; Elevated: Rare, usually indicates dehydration; Prognostic: Low albumin associated with poor outcomes in cardiac patients
    • Total Protein - Decreased: Suggests malnutrition, liver disease, or kidney protein loss; Elevated: Often indicates dehydration; Must evaluate: With albumin to determine composition
    • Albumin/Globulin Ratio - Decreased: May indicate infection, autoimmune disease, or malignancy; Elevated: Suggests malnutrition or liver disease; Interpretation: Requires protein electrophoresis for specific diagnosis
    • Globulin - Elevated: Suggests chronic infection, autoimmune disease, or malignancy; Decreased: Indicates immunodeficiency or severe liver disease; Pattern: Specific patterns on protein electrophoresis aid diagnosis
    • Free T3 - Elevated: Hyperthyroidism causing tachycardia and increased cardiac demand; Decreased: Hypothyroidism reducing cardiac output; Context: Interpret with TSH and Free T4 for accurate thyroid assessment
    • Free T4 - Elevated: Indicates hyperthyroidism with increased metabolic rate; Decreased: Hypothyroidism reducing metabolic rate; Primary test: For thyroid dysfunction screening in cardiac patients
    • TSH - Elevated (>4.0): Primary hypothyroidism requiring hormone replacement; Suppressed (<0.4): Hyperthyroidism or over-replacement; Sensitive test: Best initial screening for thyroid disease; Reference range: Optimized ranges now 0.4-2.5 mIU/L for some labs
    • HbA1c - Elevated (≥6.5%): Diagnostic for diabetes; 5.7-6.4%: Prediabetes category; <5.7%: Normal glucose metabolism; Represents: Average blood glucose over 2-3 months; Monitoring: Every 3-6 months for treated diabetes
    • Estimated Average Glucose (eAG) - Calculated from HbA1c: Estimates average blood glucose; Correlates: Approximately with home glucose meter readings; Target: <130 mg/dL for most diabetic patients; Helps: Patients understand HbA1c in familiar glucose units
    • Red Blood Cell Count - Decreased: Anemia reducing oxygen-carrying capacity; Elevated: Polycythemia increasing blood viscosity; Critical for: Assessment of oxygen delivery to cardiac tissue
    • Hemoglobin - Decreased: Anemia impairing oxygen delivery and cardiac workload; Elevated: Polycythemia increasing thrombotic risk; Goals: 7-9 g/dL in critically ill; Normal transfusion at <7 g/dL
    • Hematocrit - Decreased: Associated with anemia and reduced oxygen-carrying capacity; Elevated: May indicate dehydration or polycythemia; Reflects: Proportion of blood volume occupied by red blood cells
    • White Blood Cell Count - Elevated (>11,000): Infection, stress, or leukemia; Decreased (<4,500): Immunosuppression or bone marrow disorder; Interpretation: Consider differential count for specific diagnosis
    • Platelet Count - Decreased (<150,000): Bleeding risk and thrombocytopenia; Elevated (>400,000): Thrombotic risk or reactive increase; Normal: Essential for appropriate hemostasis
    • CBC Differential - Neutrophils elevated: Bacterial infection; Lymphocytes elevated: Viral infection; Eosinophils elevated: Parasitic or allergic condition; Complete differential: Identifies specific white cell abnormalities
  • Associated Organs
    • Calcium - Primary organ: Parathyroid glands, bones, intestines; Related diseases: Hyperparathyroidism, osteoporosis, kidney disease; Cardiac complications: Arrhythmias, myocardial calcification, hypertension
    • Alkaline Phosphatase - Primary organ: Liver, bones, intestines; Related diseases: Liver cirrhosis, Paget disease, biliary obstruction; Cardiac implications: Indicates hepatic dysfunction affecting metabolic capacity
    • hs-CRP - Primary organ: Produced by liver in response to IL-6; Related diseases: Atherosclerosis, myocarditis, acute coronary syndrome; Cardiac complications: Plaque destabilization, endothelial dysfunction, thrombosis
    • Lipoprotein(a) - Primary organ: Liver (synthesis); Related diseases: Familial hypercholesterolemia, cardiovascular disease; Cardiac complications: Thrombotic events, accelerated atherosclerosis, valve disease
    • SGOT (AST) - Primary organ: Liver, heart, skeletal muscle; Related diseases: Acute myocardial infarction, hepatitis, cirrhosis; Cardiac complications: Released in MI correlating with myocardial necrosis
    • SGPT (ALT) - Primary organ: Liver predominantly; Related diseases: Viral hepatitis, non-alcoholic fatty liver disease, steatohepatitis; Cardiac implications: Statin-induced liver injury may limit lipid-lowering therapy
    • Uric Acid - Primary organ: Kidneys (excretion), liver (synthesis); Related diseases: Gout, kidney disease, metabolic syndrome; Cardiac complications: Hypertension, inflammation, atherosclerosis progression
    • Homocysteine - Primary organ: Metabolized by liver and kidneys; Related diseases: Hypertension, thromboembolism, atherosclerosis; Cardiac complications: Endothelial dysfunction, thrombosis, plaque formation
    • Apolipoprotein A1 - Primary organ: Liver (synthesis); Related diseases: Hypoalphalipoproteinemia, atherosclerosis; Cardiac protection: Component of HDL providing reverse cholesterol transport
    • Apolipoprotein B - Primary organ: Liver (synthesis); Related diseases: Familial defective apoB, atherosclerosis; Cardiac complications: Indicates number of atherogenic particles predicting CAD
    • Apo B/A1 Ratio - Composite indicator: Reflects balance of atherogenic vs protective lipoproteins; Related diseases: Dyslipidemia, metabolic syndrome, coronary disease; Cardiac risk: Superior predictor of atherosclerotic events
    • BUN and Creatinine - Primary organ: Kidneys; Related diseases: Acute kidney injury, chronic kidney disease, diabetic nephropathy; Cardiac complications: Uremia affecting cardiac function, medication safety limiting
    • BUN/Creatinine Ratio - Diagnostic indicator: Differentiates prerenal vs intrinsic kidney disease; Related conditions: Dehydration, heart failure, liver disease; Cardiac significance: Identifies cardiorenal syndrome
    • GGT - Primary organ: Liver, kidney, pancreas; Related diseases: Alcoholic liver disease, biliary obstruction, cholangitis; Cardiac implications: Marker of hepatic dysfunction affecting medication metabolism
    • Iron - Primary organ: Bone marrow (RBC production), intestines (absorption); Related diseases: Hemochromatosis, iron deficiency anemia; Cardiac complications: Cardiomyopathy from excess iron, anemia from deficiency
    • TIBC and Transferrin Saturation - Primary organ: Liver (transferrin production); Related diseases: Iron deficiency, iron overload; Cardiac impact: Severe anemia causes high-output heart failure; Hemochromatosis causes restrictive cardiomyopathy
    • Bilirubin - Primary organ: Liver (processing), bile ducts (excretion); Related diseases: Hemolytic anemia, Gilbert syndrome, biliary obstruction; Cardiac complications: Hepatic cirrhosis development affecting cardiac hemodynamics
    • Lipid Profile - Primary organ: Liver (production), intestines (absorption); Related diseases: Atherosclerosis, familial hypercholesterolemia, metabolic syndrome; Cardiac complications: Coronary artery disease, myocardial infarction, sudden cardiac death
    • Albumin and Total Protein - Primary organ: Liver (synthesis); Related diseases: Cirrhosis, nephrotic syndrome, malnutrition; Cardiac implications: Compromised cardiac protein synthesis and myocardial contractility
    • Albumin/Globulin Ratio - Composite indicator: Reflects protein synthesis capacity; Related conditions: Liver disease, autoimmune disease, malignancy; Cardiac significance: Predicts liver dysfunction limiting cardiac therapy options
    • Free T3 and Free T4 - Primary organ: Thyroid gland; Related diseases: Graves disease, Hashimoto thyroiditis, thyroid cancer; Cardiac complications: Hyperthyroidism causes atrial fibrillation and increased MI risk; Hypothyroidism causes bradycardia
    • TSH - Primary organ: Pituitary gland with thyroid feedback; Related diseases: Primary hypothyroidism, secondary hypothyroidism; Cardiac impact: Thyroid disease significantly affects cardiac function and arrhythmia risk
    • HbA1c and eAG - Primary organ: Pancreas (insulin production), multiple tissues (glucose metabolism); Related diseases: Type 1 diabetes, type 2 diabetes, gestational diabetes; Cardiac complications: Accelerated atherosclerosis, increased MI risk, autonomic dysfunction
    • CBC - Complete Hemogram - Primary organ: Bone marrow (RBC, WBC, platelet production); Related diseases: Anemia, leukemia, thrombocytopenia; Cardiac complications: Severe anemia causes high-output failure; Infections increase cardiac demand
  • Follow-up Tests
    • Calcium - Follow-up if abnormal: PTH (parathyroid hormone), vitamin D 25-hydroxy, phosphate levels; Imaging: X-ray for arterial calcification if elevated; Monitoring: Every 6-12 months if on PTH therapy
    • Alkaline Phosphatase - If elevated: 5' nucleotidase, GGT for specificity; Ultrasound: Liver ultrasound if liver disease suspected; Bone imaging: X-ray or DEXA if bone disease indicated
    • hs-CRP - If elevated: Repeat testing in 2-4 weeks to confirm; Consider: Lifestyle intervention trial; Advanced testing: Lipoprotein-associated PLA2 (Lp-PLA2); Imaging: Consider coronary calcium scoring or stress testing
    • Lipoprotein(a) - If elevated (>30): Genetic counseling for familial hypercholesterolemia; Family screening: Test first-degree relatives; Imaging: Coronary calcium scoring or stress testing; Monitoring: Repeat every 5 years if stable
    • SGOT (AST) - If elevated: ALT, bilirubin, prothrombin time to assess liver; Ultrasound: Liver ultrasound if cirrhosis suspected; Cardiac assessment: Troponin if myocardial infarction possible; Monitoring: Repeat in 4-6 weeks if mild elevation
    • SGPT (ALT) - If elevated: AST ratio assessment, bilirubin, ALP, albumin for complete liver panel; Hepatitis serology: If viral hepatitis suspected; Ultrasound: Consider if persistent elevation; Monitoring: Statin-induced elevation often resolves or requires dose adjustment
    • Uric Acid - If elevated: Consider rheumatology referral for gout; 24-hour urine uric acid: To determine over/under excretion; Imaging: X-ray if tophaceous gout present; Monitoring: Repeat if starting urate-lowering therapy
    • Homocysteine - If elevated (>11): B vitamin levels (B6, B12, folate) for supplementation; Consider: MTHFR genetic testing; Start: B vitamin therapy with monitoring; Repeat: After 8-12 weeks of supplementation
    • Apolipoprotein A1 - If low (<120): Genetic counseling for familial hypoalphalipoproteinemia; Family screening: Lipid profile in relatives; Consider: HDL-raising therapy if other risk factors; Monitoring: With lipid panel responses to therapy
    • Apolipoprotein B - If elevated (>130): Complete lipid panel assessment; Consider: Advanced particle testing; Imaging: Carotid intima-media thickness or coronary calcium; Monitoring: With lipid-lowering therapy responses
    • Apo B/A1 Ratio - If elevated (>0.8): Institute lipid-lowering therapy; Genetic evaluation: If severely elevated; Advanced testing: Lipoprotein subclass analysis; Monitoring: Repeat every 3-6 months during therapy
    • BUN and Creatinine - If abnormal: Calculate eGFR (estimated glomerular filtration rate); Urinalysis: Assess proteinuria; Renal ultrasound: If acute kidney injury suspected; Nephrology referral: If eGFR <30 mL/min/1.73m²
    • BUN/Creatinine Ratio - If elevated (>20): Assess hydration status; Diuretic use review: May need adjustment; Monitoring: Repeat after fluid repletion; Identify: Cardiorenal syndrome if applicable
    • GGT - If elevated: Complete liver panel with AST, ALT, bilirubin; Ultrasound: Liver ultrasound to assess structure; Consider: Alcohol counseling if alcohol use disorder present; Monitoring: Repeat in 4-8 weeks
    • Iron - If abnormal: Ferritin level, TIBC assessment; Hemochromatosis screening: Genetic testing (HFE) if elevated; Iron deficiency workup: GI bleeding studies if low; Monitor: CBC with indexes for anemia tracking
    • TIBC and Transferrin Saturation - If abnormal: Iron studies with ferritin; Bone marrow biopsy: If aplasia suspected; Imaging: GI imaging if iron deficiency; Genetic testing: HFE mutation if hemochromatosis indicated
    • Bilirubin - If elevated: Determine direct vs indirect fraction; Additional tests: Complete liver panel, reticulocyte count; Imaging: Ultrasound if obstruction suspected; Hemolysis evaluation: If primarily indirect bilirubin
    • Lipid Panel - If abnormal: Repeat fasting in 4-6 weeks to confirm; Advanced testing: Particle subclass analysis, Lp(a); Imaging: Carotid ultrasound, coronary calcium scoring if high-risk; Stress testing: Consider if symptomatic
    • Albumin and Total Protein - If decreased: Complete liver function panel; Prothrombin time: Assess synthetic function; Ultrasound: Liver ultrasound to assess cirrhosis; Consider: Gastrointestinal bleeding workup if very low
    • Albumin/Globulin Ratio and Globulin - If abnormal: Protein electrophoresis for specific fractionation; Immunoglobulin levels: If malignancy suspected; Imaging: Chest X-ray if lymphoproliferative disorder possible; Follow-up: Varies by specific diagnosis
    • Free T3 and Free T4 - If abnormal: TSH confirmation of thyroid disorder; Thyroid antibodies: TPO and anti-thyroglobulin if autoimmune suspected; Consider: Thyroid ultrasound if nodules suspected; Endocrinology referral: For complex thyroid disease
    • TSH - If abnormal: Free T4 level confirmation; Thyroid antibodies: Screening for autoimmune thyroiditis; Imaging: Thyroid ultrasound if indicated; Monitoring: Repeat TSH 6-8 weeks after therapy initiation
    • HbA1c - If elevated (≥5.7%): Fasting glucose and 2-hour glucose tolerance test; Retinopathy screening: Annual comprehensive eye exam; Microalbumin screening: Urinary albumin for early nephropathy detection; Monitoring: Every 3-6 months if diabetic
    • eAG - If elevated: Institute diabetes management; Continuous glucose monitoring: Consider if frequent hyperglycemia; Dietary consultation: Certified diabetes educator referral; Medication adjustment: Based on trend and HbA1c
    • CBC - If abnormal: Peripheral blood smear if cell count abnormality; Reticulocyte count: If anemia present; Bone marrow biopsy: If severe cytopenias; Hematology referral: For unexplained abnormalities; Monitoring: Repeat in 4-6 weeks for trends
  • Fasting Required?
    • Fasting Required: YES - 8-12 hours overnight fast recommended for this comprehensive panel
    • Lipid Profile component: Mandatory fasting for 8-12 hours to prevent dietary triglyceride interference; Triglycerides specifically: Elevated 2-4 hours after meals, significantly affecting test accuracy
    • HbA1c and eAG: Not affected by fasting; can be drawn any time; however, for test standardization with other components, fasting preferred
    • CBC and other components: Not strictly fasting-dependent but fasting recommended for consistency with lipid panel requirements
    • Water intake: Acceptable during fasting period; recommended to maintain hydration for better vein access
    • Medications: Continue taking regular cardiac and other maintenance medications with small sip of water unless otherwise instructed by physician
    • Medications to avoid: Avoid lipid-altering supplements or herbals for 24 hours before test; Avoid excess vitamin C and niacin; Inform lab of all supplements and herbs
    • Alcohol: Avoid alcohol for 24 hours before test; can artificially elevate triglycerides and liver enzymes
    • Dietary restrictions: Avoid unusually high-fat meals for 2-3 days before test; maintain normal diet but no large meal immediately before fasting
    • Exercise: Avoid vigorous exercise for 24 hours before test; light activity is acceptable
    • Caffeine and smoking: Avoid caffeine for 2 hours before draw; avoid smoking for 1 hour before test
    • Stress and activity: Minimize stress before testing; avoid running or rushing to appointment if possible as stress elevates cortisol and can affect results
    • Timing: Schedule test in morning (7-9 AM preferred) for standardized diurnal variation comparison; fasting for 8-12 hours means typical evening meal last food intake
    • Recent illness: Postpone testing if acute illness present; conditions like infection temporarily elevate inflammatory markers and liver enzymes
    • Menstrual cycle: Women may experience slight changes in some values; consider timing if possible, though not critical
    • Confirmation: Repeat test at minimum 2 weeks apart if abnormalities found to rule out laboratory error or transient elevation

How our test process works!

customers
customers